Terminated PHASE3 INTERVENTIONAL 2-arm NCT00637494

A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features

A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Mifepristone vs. Placebo in the Treatment of Psychotic Symptoms in Patients With Major Depressive Disorder With Psychotic Features

Sponsor: Corcept Therapeutics

Conditions Psychosis Psychotic Depression Severe Major Depression With Psychotic Features

Interventions mifepristone placebo

Updated 10 times since 2017 Last updated: May 4, 2017 Started: Mar 31, 2008 Primary completion: Jun 30, 2014 Completion: Jun 30, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

DRC recommended stopping study as it had missed its primary endpoint

Other terminated trials from Corcept Therapeutics

See all terminations from Corcept Therapeutics

This PHASE3 trial investigates Psychosis and Psychotic Depression and is currently terminated or withdrawn. Corcept Therapeutics leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

10 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE3
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE3
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE3
Jan 2023 — Jul 2024 [monthly]

Terminated PHASE3
Dec 2022 — Jan 2023 [monthly]

Terminated PHASE3

▶ Show 5 earlier versions

Jan 2021 — Dec 2022 [monthly]

Terminated PHASE3
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE3
Jul 2017 — Jun 2018 [monthly]

Terminated PHASE3
Feb 2017 — Jul 2017 [monthly]

Terminated PHASE3
Jan 2017 — Feb 2017 [monthly]

Terminated PHASE3

First recorded

Mar 2008

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Corcept Therapeutics

Data source: Corcept Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Allentown, United States , Anaheim, United States , Atlanta, United States , Austin, United States , Aventura, United States , Cedarhurst, United States , Charleston, United States , Creve Coeur, United States , Dallas, United States , Dayton, United States and 27 more locations